SCHEMBL4622160

SCHEMBL4622160

CCCN1Cc2ccccc2CC1C(=O)NCC1C2CN(Cc3ccccc3)CC12

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 2/20 0.39
MMP3 P08254 2/20 0.39
MMP1 P03956 1/20 0.39
ADAM17 P78536 1/20 0.39
ADAM9 Q13443 1/20 0.39
HDAC8 Q9BY41 3/20 0.38
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
NAMPT P43490 2/20 0.37
MMP8 P22894 2/20 0.37
ACE P12821 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
GLA P06280 1/20 0.36
PPARD Q03181 2/20 0.36
PPARA Q07869 2/20 0.36
PPARG P37231 1/20 0.36
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4650250 0.84 CFTR (0.43) MMP3MMP8ACETDP1ALDH1A1
SCHEMBL4648640 0.83 TDP1 (0.40) MMP9MMP3MMP1ADAM17ADAM9
SCHEMBL4925547 0.82 NR1D1 (0.40) MMP9MMP3MMP1ADAM17ADAM9
SCHEMBL4649542 0.81 NAMPT (0.41) MMP9MMP3MMP1ADAM17ADAM9
SCHEMBL4922008 0.80 HDAC8 (0.51) HDAC8NAMPTTDP1NPSR1
SCHEMBL4649150 0.79 F2R (0.36) MMP3NAMPTMMP8TDP1ALDH1A1
SCHEMBL4913374 0.74 KMT2A (0.56) HDAC8
SCHEMBL1014404 0.73 S1PR5 (0.50)
SCHEMBL12191655 0.73 ACE (0.51) MMP3MMP8ACETDP1ALDH1A1
SCHEMBL4649602 0.70 CFTR (0.46) MMP3NAMPTMMP8ACETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255188-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-10-16 US claimed
EP-1904495-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-04-02 EP claimed
WO-2007007281-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO claimed
US-20080255188-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-10-16 US disclosed
EP-1904495-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-04-02 EP disclosed
WO-2007007281-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255188-A1 Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 MMP9 3432/4885MMP3 3787/4885MMP1 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.